Aoti FCF Growth

What does Aoti do? Aoti Inc generates revenue through its wound care technology products, primarily TWO2 therapy and NEXA Negative Pressure Wound Therapy (NPWT). The company's TWO2 therapy solutions include TWO2 Extremity Chamber and TWO2 Multi-Patch, designed for patient-administered treatment of chronic wounds. NEXA NPWT System is a disposable, multi-week solution for wound care, targeting healthcare providers who manage chronic wound cases. Aoti focuses on enhancing access to care and improving clinical outcomes for patients with chronic conditions, leveraging robust clinical evidence to support its products' safety and efficacy. Healthcare providers and institutions purchasing TWO2 and NEXA systems form the primary customer segment, driven by the need for clinically proven wound care solutions. The company's products are positioned to address chronic wound management globally, with emphasis on patient quality of life and health equity. Aoti's business model centers on delivering evidence-based therapies that improve patient outcomes while meeting healthcare systems' demands for effective, efficient care delivery. The company's revenue streams are derived from direct sales of TWO2 and NEXA systems to healthcare facilities and practitioners. Product offerings are structured to support both acute and chronic wound care needs, with TWO2 being a multi-modality patient-administered therapy and NEXA providing a flexible, disposable NPWT system. Aoti's focus on clinical evidence ensures its solutions align with healthcare providers' requirements for safety and efficacy in wound treatment. Aoti is one of the most popular companies on Eulerpool.